Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
102234 trials found · Page 166 of 5112
-
New smart drug targets cancer cells in advanced tumors and lung cancer
Disease control Recruiting nowThis is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer. CKD-703 is composed of a c-Met-targeting monoc…
Phase: PHASE1, PHASE2 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 01, 2026 18:01 UTC
-
New combo aims to tame lymphoma with less radiation damage
Disease control Recruiting nowThis is a prospective, multicenter Phase 2 clinical trial named the MALT-RO study, evaluating ultra-low-dose radiation therapy followed by orelabrutinib as first-line treatment for adults with Stage I-II MALT lymphoma. The study aims to determine the efficacy and safety profile o…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New hope for advanced liver cancer: drug combo under Real-World study
Disease control Recruiting nowItalian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic treatment…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 05, 2026 12:09 UTC
-
New hope for hard-to-treat lymphoma: drug combo plus stem cell transplant shows promise
Disease control Recruiting nowThis phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before autologous stem cell transplant in treating patients with d…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 03, 2026 12:07 UTC
-
New antibody may boost transplant success in tough lymphoma
Disease control Not yet recruitingThis is an investigator-initiated, open-label, single-arm, multicenter, Phase II clinical study. The study is designed to evaluate the safety and potential effectiveness of glofitamab in adults with their disease, diffuse large B-cell lymphoma (DLBCL has either not responded to i…
Phase: PHASE2 • Sponsor: American University of Beirut Medical Center • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
New chemo injection method aims to boost survival in pancreatic cancer
Disease control Not yet recruitingthis is a randomized controlled trial aims to compare between patients with locally advanced pancreatic cancer treated with EUS-guided injection of gemcitabine in addition to systemic chemotherapy, versus those who treated with the standard systemic chemotherapy alone, regarding …
Phase: PHASE2, PHASE3 • Sponsor: Assiut University • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC
-
New hope for rare heart valve patients: SAPIEN 3 trial launches in china
Disease control Not yet recruitingIn China, bicuspid aortic valve (BAV) represents a significantly high proportion of the transcatheter aortic valve replacement (TAVR) population. The application of TAVR in patients with BAV is challenging due to complex anatomy. To date, no prospective study has evaluated the Sa…
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC
-
Home visits could boost TB prevention in ethiopian children
Prevention Not yet recruitingBackground: Tuberculosis (TB), though preventable and curable, remains a major public health concern worldwide. While elimination of tuberculosis infection (TBI) is critical to TB elimination, TBI continues to represent a substantial public health burden, particularly among house…
Phase: NA • Sponsor: Dilla University • Aim: Prevention
Last updated Jun 01, 2026 18:03 UTC
-
New hope for lymphoma patients when CAR T-Cell therapy Doesn't work
Disease control Not yet recruitingThis is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 08, 2026 13:07 UTC
-
One-Time gene therapy could change pompe disease treatment
Disease control Recruiting nowThis is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of AB-1009 in adult participants with late-onset Pompe disease (LOPD).
Phase: PHASE1, PHASE2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 10, 2026 01:24 UTC
-
New valve grows with kids, could reduce surgeries
Disease control Not yet recruitingProspective, single-arm, multi-center, continued access study of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects…
Phase: NA • Sponsor: Autus Valve Technologies, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Double-Drug strike aims to halt MS early
Disease control Not yet recruitingThe HiHat trial is a Phase 2 study aimed at evaluating the safety and feasibility of sequential treatment with rituximab and cladribine in patients with relapsing-remitting multiple sclerosis (RRMS). The study follows a prospective, open-label, single-arm design, with 60 RRMS pat…
Phase: PHASE2 • Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
New eye drug could rival standard treatment for blinding disease
Disease control Recruiting nowResearchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called M…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
Could a common gout pill save legs? new trial aims to find out
Disease control Not yet recruitingChronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease, a condition in which narrowed or blocked arteries reduce blood flow to the legs. People with CLTI may have severe leg pain at rest, non-healing wounds, or gangrene, and face a high risk…
Phase: PHASE3 • Sponsor: Shin Kong Wu Ho-Su Memorial Hospital • Aim: Disease control
Last updated May 29, 2026 14:17 UTC
-
New hope for tough breast cancer: drug combo trial launches
Disease control Not yet recruitingThe study will evaluate the safety and efficacy of QLC5513 alone or in combination with QL1706 in patients with advanced or metastatic triple-negative breast cancer (TNBC) who had received ≥1 line of prior systematic therapy.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 01, 2026 18:04 UTC
-
Tooth stem cells could regrow gums and bone, replacing surgery
Disease control Not yet recruitingThe overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. It aims to develop a stem cell injection therapy that promotes the regeneration of periodon…
Phase: NA • Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
New drug cocktail aims to control follicular lymphoma early
Disease control Not yet recruitingEvaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
Revolutionary CAR-T shot? new therapy builds cancer fighters inside you
Disease control Not yet recruitingThis study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects. DIT101 is an investigational in vivo CAR-T cell therap…
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:07 UTC
-
New drug aims to stop throat cancer from coming back
Disease control Not yet recruitingThis is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to compare the efficacy and safety of Becotatug Vedotin and capecitabine as an adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal …
Phase: PHASE2 • Sponsor: Kai Hu • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
Could a biomarker test unlock better treatment for Right-Sided colon cancer?
Disease control Not yet recruitingThe aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC. Further to this, the aim is to determine whether EREG/AREG status identifies right-PTL participants who …
Phase: PHASE4 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 03, 2026 13:19 UTC